Mohammed Alshalalfa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed Alshalalfa has a total of 316 co-authors. Here are the top co-authors by number of shared publications:
- Elai Davicioni
Veracyte, Inc., South San Francisco, California
21 shared publications - Mark A. Rubin
Department for BioMedical Research, University of Bern, Bern, Switzerland
19 shared publications - Cory Abate-Shen
Columbia University, New York, New York
17 shared publications - Juan Martín Arriaga
Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA
17 shared publications - Anindita Dutta
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
16 shared publications - Anne Offermann
Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
16 shared publications
Latest Publications
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Molecular Features Underlying Discordance Between Clinical and Genomic Risk Stratification in Localized Prostate Cancer in Over 280, 000 Patients
Introduction: Although the Decipher Genomic Classifier (GC) improves risk stratification beyond standard National Comprehensive Cancer Network (NCCN) risk groups, distinct clinical discordance exists between them. Herein, we interrogate specific adverse molecular features (AMFs) associated with genomic upgrading/downgrading relative to clinical risk and evaluate their overall long-term prognostic impact on treated patients. Materials and Methods: The specific prevalence of four separate AMFs (TP53 status, PTEN inactivation, lower androgen receptor [AR] activity, and RB1 loss) was evaluated across GC and NCCN risk groups using biopsy data from 287,145 patients. Prognostic associations with distant metastasis (DM) were fully assessed in 15,109 patients with NCCN high and very high-risk disease. Results: Decipher re-classified 21% of NCCN low and favorable intermediate-risk patients as high risk, while 33% of NCCN high-risk patients were GC-lower risk. AMF prevalence associated more strongly with GC than NCCN groups. TP53 mutant-like status, PTEN inactivation, and lower AR activity were associated with NCCN–GC discordance. Within the study cohort, a high GC score was associated with significantly increased risk of DM; AMFs independently predicted DM. Patients with at least one adverse AMF and a GC score >0.60 had a predicted 5-year DM probability of 17–25%, compared to 5% for those with favorable molecular profiles and a GC score ≤0.60. Conclusions: Individual AMFs are associated with the discordance between NCCN and GC risk classifications. In patients with NCCN high-risk disease, the GC score serves as a primary prognostic driver, while AMF profiling provides additive risk stratification within specific clinical GC strata.
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Molecular Features Underlying Discordance Between Clinical and Genomic Risk Stratification in Localized Prostate Cancer in Over 280, 000 Patients
Introduction: Although the Decipher Genomic Classifier (GC) improves risk stratification beyond standard National Comprehensive Cancer Network (NCCN) risk groups, distinct clinical discordance exists between them. Herein, we interrogate specific adverse molecular features (AMFs) associated with genomic upgrading/downgrading relative to clinical risk and evaluate their overall long-term prognostic impact on treated patients. Materials and Methods: The specific prevalence of four separate AMFs (TP53 status, PTEN inactivation, lower androgen receptor [AR] activity, and RB1 loss) was evaluated across GC and NCCN risk groups using biopsy data from 287,145 patients. Prognostic associations with distant metastasis (DM) were fully assessed in 15,109 patients with NCCN high and very high-risk disease. Results: Decipher re-classified 21% of NCCN low and favorable intermediate-risk patients as high risk, while 33% of NCCN high-risk patients were GC-lower risk. AMF prevalence associated more strongly with GC than NCCN groups. TP53 mutant-like status, PTEN inactivation, and lower AR activity were associated with NCCN–GC discordance. Within the study cohort, a high GC score was associated with significantly increased risk of DM; AMFs independently predicted DM. Patients with at least one adverse AMF and a GC score >0.60 had a predicted 5-year DM probability of 17–25%, compared to 5% for those with favorable molecular profiles and a GC score ≤0.60. Conclusions: Individual AMFs are associated with the discordance between NCCN and GC risk classifications. In patients with NCCN high-risk disease, the GC score serves as a primary prognostic driver, while AMF profiling provides additive risk stratification within specific clinical GC strata.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 4
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 4
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Characteristics of GEMM cohort used and raw quantification of ATAD2 expression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Characteristics of GEMM cohort used and raw quantification of ATAD2 expression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Oligonucleotides used in this Study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Oligonucleotides used in this Study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses of MYC regulation of ATAD2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses of MYC regulation of ATAD2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analysis of ATAD2 expression in prostate cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analysis of ATAD2 expression in prostate cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ATAD2 Drives Prostate Cancer Progression to Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ATAD2 Drives Prostate Cancer Progression to Metastasis
- Open Access
- 12 January 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (4) , E108-E112
Preoperative Detection of Dual TERT Promoter Mutations in Thyroid Cancer: A Case Series
Telomerase reverse transcriptase promoter ( TERTp ) mutations are associated with aggressive thyroid cancer and are most frequently found in anaplastic and poorly differentiated thyroid cancer. Pre‐operative thyroid nodule molecular testing can detect TERTp , denoting a high risk of malignancy and possible aggressive clinical features such as extrathyroidal extension, regional lymph node metastases, and distant metastases. There are two described hot spot point mutations: the more common C228T and a C250T variant. Canonically, these mutations are mutually exclusive and drive monoallelic TERT expression. In this case series, we describe thyroid cancers where both the C228T and C250T variants were detected in preoperative thyroid nodule fine needle aspiration samples sent for Afirma molecular testing. All had co‐mutations along with BRAF p.V600E or PIK3CA p.H1047R. Each sample was sent for kinship (relatedness between individuals) analysis to confirm the DNA and RNA samples were from the same patient and not due to sample cross contamination. All cases had confirmed thyroid carcinoma on histopathology after surgical resection. To our knowledge, this is the first report of dual TERTp mutations detected in the preoperative setting in thyroid carcinoma. Clinical correlation with future cases will be of interest, particularly if cases with monoallelic dual TERT p mutations are discovered.
- 12 January 2026
- Published by Wiley in Diagnostic Cytopathology
- Vol. 54 (4) , E108-E112
Open AccessPreoperative Detection of Dual TERT Promoter Mutations in Thyroid Cancer: A Case Series
Telomerase reverse transcriptase promoter ( TERTp ) mutations are associated with aggressive thyroid cancer and are most frequently found in anaplastic and poorly differentiated thyroid cancer. Pre‐operative thyroid nodule molecular testing can detect TERTp , denoting a high risk of malignancy and possible aggressive clinical features such as extrathyroidal extension, regional lymph node metastases, and distant metastases. There are two described hot spot point mutations: the more common C228T and a C250T variant. Canonically, these mutations are mutually exclusive and drive monoallelic TERT expression. In this case series, we describe thyroid cancers where both the C228T and C250T variants were detected in preoperative thyroid nodule fine needle aspiration samples sent for Afirma molecular testing. All had co‐mutations along with BRAF p.V600E or PIK3CA p.H1047R. Each sample was sent for kinship (relatedness between individuals) analysis to confirm the DNA and RNA samples were from the same patient and not due to sample cross contamination. All cases had confirmed thyroid carcinoma on histopathology after surgical resection. To our knowledge, this is the first report of dual TERTp mutations detected in the preoperative setting in thyroid carcinoma. Clinical correlation with future cases will be of interest, particularly if cases with monoallelic dual TERT p mutations are discovered.
- Open Access
- 5 November 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (12) , 3027-3038
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
The androgen receptor (AR) is a critical driver of prostate cancer (PCa). Here, to study regulators of AR protein levels and oncogenic activity, we developed a live-cell quantitative endogenous AR fluorescent reporter. Leveraging this AR reporter, we performed genome-scale CRISPRi flow cytometry sorting screens to systematically identify genes that modulate AR protein levels. We identified and validated known AR protein regulators, including HOXB13 and GATA2, and also unexpected top hits including PTGES3—a poorly characterized gene in PCa. PTGES3 repression resulted in loss of AR protein, cell-cycle arrest and cell death in AR-driven PCa models. Clinically, analysis of PCa data demonstrates that PTGES3 expression is associated with AR-directed therapy resistance. Mechanistically, we show PTGES3 binds directly to AR, regulates AR protein stability and is necessary for AR function in the nucleus at AR target genes. PTGES3 represents a potential therapeutic target for overcoming known mechanisms of resistance to existing AR-directed therapies in PCa.
- 5 November 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (12) , 3027-3038
Open AccessGenome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
The androgen receptor (AR) is a critical driver of prostate cancer (PCa). Here, to study regulators of AR protein levels and oncogenic activity, we developed a live-cell quantitative endogenous AR fluorescent reporter. Leveraging this AR reporter, we performed genome-scale CRISPRi flow cytometry sorting screens to systematically identify genes that modulate AR protein levels. We identified and validated known AR protein regulators, including HOXB13 and GATA2, and also unexpected top hits including PTGES3—a poorly characterized gene in PCa. PTGES3 repression resulted in loss of AR protein, cell-cycle arrest and cell death in AR-driven PCa models. Clinically, analysis of PCa data demonstrates that PTGES3 expression is associated with AR-directed therapy resistance. Mechanistically, we show PTGES3 binds directly to AR, regulates AR protein stability and is necessary for AR function in the nucleus at AR target genes. PTGES3 represents a potential therapeutic target for overcoming known mechanisms of resistance to existing AR-directed therapies in PCa.